TRANEX
- Conditions
- Burn injuryTherapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2024-513573-49-00
- Lead Sponsor
- Maasstad Ziekenhuis Stichting
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 95
1. Patients scheduled for burn excisional surgery 2. An expected blood loss of =250ml based on the estimation by the performing surgeon on the basis of: (1) 2 % body surface area excision planned (100-200 cc / %TBSA, based on retrospective data from Burn Centre Rotterdam), (2) operation technique used (some techniques show more blood loss than others), (3) time after burn trauma (i.e. expected healing). - =18 year
Patients with a recorded coagulopathy in their history - Severe kidney failure (creatinine >500 umol/L) - Allergy for tranexamic acid - Acute venous-/arterial thrombosis (ongoing thrombosis). A history of thrombosis is NOT an exclusion criterion - Diffuse intravascular coagulation - Pregnancy - History of epilepsy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method